1
|
Duta TF, Rizki DR, Purnama A, Rademaker M, Wollina U, Acharya Y, Abdeen Z, Rosa SGV, Nielsen HB, Subbaram K. Essential oils for COVID-19 management: A systematic review of randomized controlled trials. Narra X 2023; 1. [DOI: 10.52225/narrax.v1i2.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/04/2023] [Imported: 09/04/2023]
Abstract
Essential oils can be a beneficial adjuvant therapy in managing coronavirus disease 2019 (COVID-19). This systematic review aims to evaluate the efficacy of essential oils in ameliorative COVID-19-related symptoms. Published studies reporting the efficacy of essential oils as adjuvant therapy for COVID-19 were screened on Scillit, Scopus, SciFinder, and PubMed (December 7th, 2022). Inclusion criteria include the randomized controlled trials (RCTs) participated by those diagnosed with COVID-19 and treated with essential oils as adjuvant therapy. Quality assessment was carried out using Cochrane ‘risk-of-bias’ 2.0 tool. A total of 2112 records were retrieved from the initial screening, which was reduced to four publications (n=344 individuals). The foregoing studies reported that essential oils could improve the recovery rate, alleviate post-COVID-19 fatigue, and prevent disease progression. Regarding their potential antiviral activity, better designed studies are needed. In conclusion, essential oils as adjuvant therapy are beneficial in ameliorating mild COVID-19 symptoms.
Collapse
|
2
|
Viveiros Rosa SG, Farfán Cano GG. Resuscitation goals in septic shock: fluid therapy and vasoactive drugs, an integrative review. Trends Infect Global Health 2023; 3:1-9. [DOI: 10.24815/tigh.v3i1.31539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/13/2023] [Imported: 07/13/2023]
Abstract
Severe sepsis and septic shock are complex syndromes with high mortality that frequently affect ICU patients. Contributions such as the Surviving Sepsis campaign have led to the issuing of guidelines for managing these patients. This manuscript aims to provide a review of state of the art using a systematic review of resuscitation and the use of vasopressors in patients with septic shock. Using MESH terms and Boolean operators, systematic research for information was carried out in PubMed in February 2023. We included 28 articles of which 18 were selected using the prism algorithm that met the inclusion criteria (analysis of septic shock, fluid resuscitation, or the use of vasopressors in septic shock in humans). In conclusion, the management of septic shock should be performed based on clear objectives to improve outcomes, for which maintenance of physiological levels of oxygenation, serum lactate, and mean arterial blood pressure are crucial.
Collapse
|
3
|
Viveiros-Rosa SG, Mendes CDS, Farfán-Cano GG, El-Shazly M. The race for clinical trials on Omicron-based COVID-19 vaccine candidates: Updates from global databases. Narra J 2022; 2:e88. [PMID: 38449904 PMCID: PMC10914133 DOI: 10.52225/narra.v2i3.88] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 10/30/2022] [Indexed: 11/07/2022]
Abstract
The coronavirus disease 2019 (COVID-19) has caused more than 6.5 million deaths globally as of June 10, 2022. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has the greatest transmission rate and can cause hospitalization in vaccinated individuals. It has been the most distinct SARS-CoV-2 variant of concern to date. The existing inactivated vaccines made with the wild-type strain are less efficient to prevent disease and/or hospitalization associated with the Omicron variant, even after a booster dose. Hence, it is crucial to develop new vaccines that are effective against this variant. The objective of this study was to summarize the data on existing clinical trials for new COVID-19 vaccines formulated against Omicron variant. Clinical trials from the international clinical trials registry platforms were searched and analyzed. As of June 10, 2022, a total of 15 clinical trials are available consisting of six and nine clinical trials of inactivated and messenger RNA (mRNA)-based vaccine candidates containing the Omicron variant, respectively. Those trials are evaluating four inactivated and four mRNA-based vaccine candidates. Although Omicron-specific vaccines are highly desired, their development is challenging since the SARS-CoV-2 variant formation is still unpredictable. Although two vaccines from Pfizer and Moderna have been approved for emergency use in the US and the UK for Omicron variant, the Asian pharmaceutical companies such as CNBG (Sinopharm), Sinovac, and Shifa Pharmed also have Phase 3 clinical trials under development and almost all clinical trials are expected to be completed in 2023. These results should help guide academics and policymakers in the COVID-19 vaccine field regarding investments in updated booster doses against the SARS-CoV-2 Omicron variant.
Collapse
|
4
|
Ophinni Y, Frediansyah A, Sirinam S, Megawati D, Stoian AM, Enitan SS, Akele RY, Sah R, Pongpirul K, Abdeen Z, Aghayeva S, Ikram A, Kebede Y, Wollina U, Subbaram K, Koyanagi A, Al Serouri A, Blaise Nguendo-Yongsi H, Edwards J, Sallam DE, Khader Y, Viveiros-Rosa SG, Memish ZA, Amir-Behghadami M, Vento S, Rademaker M, Sallam M. Monkeypox: Immune response, vaccination and preventive efforts. Narra J 2022; 2:e90. [PMID: 38449905 PMCID: PMC10914130 DOI: 10.52225/narra.v2i3.90] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2022] [Accepted: 10/20/2022] [Indexed: 02/05/2023]
Abstract
Infectious threats to humans are continuously emerging. The 2022 worldwide monkeypox outbreak is the latest of these threats with the virus rapidly spreading to 106 countries by the end of September 2022. The burden of the ongoing monkeypox outbreak is manifested by 68,000 cumulative confirmed cases and 26 deaths. Although monkeypox is usually a self-limited disease, patients can suffer from extremely painful skin lesions and complications can occur with reported mortalities. The antigenic similarity between the smallpox virus (variola virus) and monkeypox virus can be utilized to prevent monkeypox using smallpox vaccines; treatment is also based on antivirals initially designed to treat smallpox. However, further studies are needed to fully decipher the immune response to monkeypox virus and the immune evasion mechanisms. In this review we provide an up-to-date discussion of the current state of knowledge regarding monkeypox virus with a special focus on innate immune response, immune evasion mechanisms and vaccination against the virus.
Collapse
Affiliation(s)
- Youdiil Ophinni
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
- Laboratory of Host Defense, WPI Immunology Frontier Research Center (IFReC), Osaka University, Osaka, Japan
| | - Andri Frediansyah
- PRTPP-National Research and Innovation Agency (BRIN), Yogyakarta, Indonesia
| | - Salin Sirinam
- Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - Dewi Megawati
- Department of Veterinary Pathobiology, School of Veterinary Medicine, University of Missouri, Columbia, MO, United States
- Department of Microbiology and Parasitology, School of Medicine, Universitas Warmadewa, Bali, Indonesia
| | - Ana M. Stoian
- Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, CA, United States
| | - Seyi S. Enitan
- Department of Medical Laboratory Science, Babcock University, Ilishan-Remo, Nigeria
| | - Richard Y. Akele
- Department of Biomedical Science, School of Applied Science, University of Brighton, London, United Kingdom
| | - Ranjit Sah
- Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal
| | - Krit Pongpirul
- Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
- Bumrungrad International Hospital, Bangkok, Thailand
| | - Ziad Abdeen
- Department of Community Health, Faculty of Medicine, Al-Quds University, Jerusalem
| | - Sevda Aghayeva
- Department of Gastroenterology, Baku Medical Plaza Hospital, Baku, Azerbaijan
| | - Aamer Ikram
- National Institute of Heath, Islamabad, Pakistan
| | - Yohannes Kebede
- Department of Health, Behavior and Society, Faculty of Public Health, Jimma University, Jimma, Ethiopia
| | - Uwe Wollina
- Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
| | - Kannan Subbaram
- School of Medicine, The Maldives National University, Maldives
| | - Ai Koyanagi
- Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Barcelona, Spain
| | | | - H. Blaise Nguendo-Yongsi
- Department of Epidemiology, School of Health Sciences, Catholic University of Central Africa, Yaoundé, Cameroon
| | - Jeffrey Edwards
- Medical Research Foundation of Trinidad and Tobago, Port of Spain, Trinidad
| | - Dina E. Sallam
- Department of Pediatrics and Pediatric Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Yousef Khader
- The Center of Excellence for Applied Epidemiology, The Eastern Mediterranean Public Health Network (EMPHNET), Amman, Jordan
| | | | - Ziad A. Memish
- Research & Innovation Centre, King Saud Medical City, Ministry of Health, Riyadh, Kingdom of Saudi Arabia
- College of Medicine, AlFaisal University, Riyadh, Kingdom of Saudi Arabia
| | - Mehrdad Amir-Behghadami
- Iranian Center of Excellence in Health Management, Department of Health Service Management, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sandro Vento
- Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia
| | - Marius Rademaker
- Clinical Trial New Zealand, Waikato Hospital Campus, Hamilton, New Zealand
| | - Malik Sallam
- Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, Jordan
- Department of Clinical Laboratories and Forensic Medicine, Jordan University Hospital, Amman, Jordan
- Department of Translational Medicine, Faculty of Medicine, Lund University, Malmö, Sweden
| |
Collapse
|
5
|
Park SH, Hong SH, Kim K, Lee SW, Yon DK, Jung SJ, Abdeen Z, Brahim Ahmed MLC, Serouri AA, Al‐Herz W, Subbaram K, Shaik Syed P, Ali S, ALI KOSAR, Al‐Shamsi HO, Baatarkhuu O, Nielsen HB, BERNINI‐CARRI E, Bondarenko A, Cassell A, Cham A, Chua MLK, Dadabhai S, Darre T, Davtyan H, Dragioti E, East B, Jeffrey Edwards R, Ferioli M, Georgiev T, Ghandour L, Harapan H, Hsueh P, Ikram A, Inoue S, Jacob L, Janković S, Jayarajah U, Jesenak M, Kakodkar P, Kapata N, Kebede Y, Khader Y, Kifle M, Koh D, Maleš VK, Kotfis K, Koyanagi A, Kretchy J, Lakoh S, Lee J, Lee JY, Mendonça MDLL, Ling L, Llibre‐Guerra J, Machida M, Makurumidze R, Mallah S, Memish ZA, MENDOZA IVAN, Moiseev S, Nadasdy T, Nahshon C, ÑAMENDYS‐SILVA SILVIOA, Yongsi BN, Nicolasora AD, Nugmanova Z, Oh H, Oksanen A, OWOPETU OLUWATOMI, Ozguler ZO, Perez GE, Pongpirul K, Rademaker M, Radojevic N, Roca A, Rodriguez‐Morales AJ, Viveiros Rosa SG, Roshi E, SAEED KMI, Sah R, Sakakushev B, Sallam DE, SATHIAN BRIJESH, Schober P, Simonović Z, Singhal T, Skhvitaridze N, Solmi M, Tizaoui K, TLHAKANELO JOHNTHATO, Torales J, Torres‐Roman S, Tsartsalis D, Tsolmon J, Vieira DN, Wanghi G, Wollina U, Xu R, Yang L, Zia K, Zildzic M, Il Shin J, Smith L. Non‐Pharmaceutical Interventions Reduce the Incidence, and Mortality of COVID‐19: A Study based on the Survey from the International COVID‐19 Research Network (ICRN). J Med Virol 2022. [DOI: https://doi.org/10.1002/jmv.28354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
| | - Sung Hwi Hong
- Yonsei University College of MedicineSeoulRepublic of Korea
| | - Kwanghyun Kim
- Department of Preventive Medicine, Yonsei University College of MedicineSeoulKorea
- Department of Public HealthYonsei UniversitySeoulKorea
| | - Seung Won Lee
- Department of Data Science, Sejong University College of Software ConvergenceSeoulSouth Korea
- Department of Precision Medicine, Sungkyunkwan University School of MedicineSuwonRepublic of Korea
| | - Dong Keon Yon
- Medical Science Research Institute, Kyung Hee University College of MedicineSeoulSouth Korea
| | - Sun Jae Jung
- Department of Public HealthYonsei UniversitySeoulKorea
| | - Ziad Abdeen
- Department of Emergency Medicine, Augusta Victoria Hospital, Address: Al Tour, East Jerusalem
| | | | | | | | - Kannan Subbaram
- School of Medicine, The Maldives National University School of MedicineMaldives
| | - P. Shaik Syed
- School of Medicine, The Maldives National University School of MedicineMaldives
| | - Sheeza Ali
- School of Medicine, The Maldives National University School of MedicineMaldives
| | - KOSAR ALI
- University of Sulaimani college of medicine
| | - Humaid O. Al‐Shamsi
- Burjeel Cancer Institute, Burjeel Medical City, Abu DhabiUnited Arab Emirates
| | - Oidov Baatarkhuu
- Department of Infectious Diseases, Mongolian National University of Medical Sciences
| | - Henning Bay Nielsen
- Department of Anesthesia and Intensive Care, Zealand University Hospital RoskildeRoskildeDenmark
- Department of Nutrition, Exercise and Sports, Faculty of Science, University of CopenhagenDenmark
| | | | | | | | | | | | - Sufia Dadabhai
- Johns Hopkins Bloomberg School of Public Health; BlantyreMalawi
| | - Tchin Darre
- Department of Pathology, University of LoméTogo
| | | | - Elena Dragioti
- Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linköping UniversityLinköpingSweden
| | - Barbora East
- 3rd, Department of Surgery, 1st Medical Faculty of Charles University, Motol University HospitalPrague, Czech Republic
| | | | - Martina Ferioli
- IRCCS Azienda Ospedaliero Universitaria di Bologna, Respiratory and Critical Care UnitBolognaItaly
- Department of Clinical, Integrated and Experimental Medicine (DIMES), Alma Mater Studiorum UniversityBolognaItaly
| | | | | | - Harapan Harapan
- Medical Research UnitUniversitas Syiah KualaBanda AcehIndonesia
| | - Po‐Ren Hsueh
- Departments of Laboratory Medicine and Internal Medicine, China Medical University HospitalChina Medical UniversityTaichungTaiwan
| | | | - Shigeru Inoue
- Tokyo Medical University, Department of Preventive Medicine and Public Health
| | - Louis Jacob
- Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Dr. Antoni Pujadas, 42, Sant Boi de LlobregatBarcelona08830Spain
- Faculty of Medicine, University of Versailles Saint‐Quentin‐en‐Yvelines78180Montigny‐le‐BretonneuxFrance
| | | | - Umesh Jayarajah
- Postgraduate Institute of Medicine, University of ColomboSri Lanka
| | - Milos Jesenak
- Department of Pediatrics, Jessenius Faculty of Medicine in MartinComenius University in Bratislava, University Teaching Hospital in Martin
| | | | | | - Yohannes Kebede
- Department of Health, Behavior and Society, Jimma UniversityEthiopia
| | | | - Meron Kifle
- Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of OxfordOxfordUK
| | - David Koh
- Saw Swee Hock School of Public Health, National University of Singapore
| | | | - Katarzyna Kotfis
- Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in SzczecinPoland
| | - Ai Koyanagi
- Parc Sanitari San Joan de Deu, ICREA, CIBERSAM, ISCIII
| | - James‐Paul Kretchy
- Public Health Unit, School of Medicine and Health Sciences, Central University, P. O. Box2305AccraGhana
| | - Sulaiman Lakoh
- College of Medicine and Allied Health Sciences, University of Sierra Leone
| | - Jinhee Lee
- Yonsei University Wonju College of Medicine
| | | | | | | | | | - Masaki Machida
- Tokyo Medical University, Department of Preventive Medicine and Public Health
| | - Richard Makurumidze
- University of Zimbabwe Faculty of Medicine and Health Sciences; Family Medicine, Global and Public Health Unit
| | - Saad Mallah
- Royal College of Surgeons in Ireland ‐Bahrain
| | - Ziad A Memish
- Director Research and Innovation Center, King Saud Medical City, Ministry of health
| | - IVAN MENDOZA
- Tropical Cardiology. Central University of Venezuela
| | | | | | - Chen Nahshon
- Department of Gynecologic Surgery & Oncology, Carmel Medical Center, HaifaIsrael
| | - SILVIO A. ÑAMENDYS‐SILVA
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; Instituto Nacional de CancerologiaMexico CityMexico
| | | | - Amalea Dulcene Nicolasora
- Molecular Biology Laboratory, Research Institute for Tropical Medicine, Alabang, Muntinlupa CityPhilippines1781
| | | | - Hans Oh
- University of Southern California
| | - Atte Oksanen
- Faculty of social sciencesTampere UniversityFinland
| | - OLUWATOMI OWOPETU
- Department of Community Medicine, University College HospitalIbadanNigeria
| | | | | | | | - Marius Rademaker
- Marius Rademaker Waikato Clinical Campus, University of Auckland Medical SchoolHamiltonNew Zealand
| | | | - Anna Roca
- MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, The Gambia
| | - Alfonso J. Rodriguez‐Morales
- Grupo de Investigación BiomedicinaFaculty of Medicine, Fundación Universitaria Autónoma de las AmericasPereiraColombia
- Universidad Cientifica del SurLimaPeru
| | | | | | | | - Ranjit Sah
- Tribhuvan University Teaching Hospital, Institute of Medicine
| | - Boris Sakakushev
- RIMU/Research Institute of Medical University Plovdiv
- Chair of Propedeutics of Surgical Diseases
- University Hospital St George Plovdiv
| | - Dina Ebrahem Sallam
- Pediatrics & Pediatric Nephrology Department, Faculty of MedicineAin Shams UniversityCairoEgypt
| | - BRIJESH SATHIAN
- Geriatrics and long term care department, Rumailah HospitalDohaQatar
| | - Patrick Schober
- Amsterdam UMC location Vrije Universiteit Amsterdam, Department of AnesthesiologyAmsterdamThe Netherlands
| | | | - Tanu Singhal
- Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute
| | | | - Marco Solmi
- Department of Psychiatry, University of OttawaOntarioCanada
- Department of Mental HealthThe Ottawa HospitalOntarioCanada
- Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa Ottawa Ontario
- Department of Child and Adolescent Psychiatry, Charité UniversitätsmedizinBerlinGermany
| | - kalthoum Tizaoui
- Laboratory of Microorganisms and Actives Biomolecules, Faculty of Sciences of TunisUniversity Tunis El Manar
| | | | - Julio Torales
- National University of Asunción, School of Medical SciencesParaguay
| | - Smith Torres‐Roman
- South American Center for Education and Research in Public Health, Universidad Norbert WienerLima15108Peru
| | - Dimitrios Tsartsalis
- Department of Emergency Medicine, Hippokration Hospital, Address: Leof Vasilissis Sofias 8011527AthensGreece
| | | | | | - Guy Wanghi
- University of Kinshasa Faculty of Medicine
| | - Uwe Wollina
- Department of Dermatology and Allergology, Städtisches Klinikum Dresden – Academic Teaching HospitalDresdenGermany
| | - Ren‐He Xu
- Faculty of Health Sciences, University of Macau
| | - Lin Yang
- Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services; School of Medicine, University of CalgaryCalgaryCanada
| | - Kashif Zia
- School of Health and Wellbeing, University of Glasgow, U.K
| | | | - Jae Il Shin
- Department of Pediatrics, Yonsei University College of MedicineSeoulRepublic of Korea
| | - Lee Smith
- Centre for Health Performance and WellbeingAnglia Ruskin University, Cambridge, UK, CB1 1PT
| |
Collapse
|
6
|
Rayhan MA, Mudatsir M, Nurjannah N, Ichsan I, Amir-Behghadami M, Khader YS, Koyanagi A, Sah R, Viveiros-Rosa SG, Mamun MA, Lemu YK, Bouchra A, Linguissi LSG, Ikram A, Sallam DE, Parperis K, Wollina U, Rademaker M, Vento S, Usman S. Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia. Narra J 2022. [DOI: http://doi.org/10.52225/narra.v2i2.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to determine the acceptance of and willingness to purchase a hypothetical COVID-19 vaccine in the general population of Aceh, a holistic Shariah law implementation province in Indonesia. An online cross-sectional study was conducted using a quota sampling technique between 1 to 24 September 2021. To determine hypothetical vaccine acceptance, respondents were asked if they were willing to accept vaccines with combinations of either 50% or 95% effectiveness and either 5% or 20% risk of adverse effects. Willingness to purchase was assessed by asking whether the participants would pay for such vaccines at certain price points. Logistic regression analysis was used to assess the associated determinants. Out of 377 respondents included in the final analysis, 86.5% were willing to accept a COVID-19 vaccine with 95% effectiveness and 5% adverse effects. The acceptance rate dropped to 45.1% if the risk of adverse effects was 20%. Vaccines with 50% effectiveness and 5% adverse effects were acceptable to 42.2% but the acceptance went down to 17.2% if the risk of adverse effects increased to 20%. Multivariate analysis found that men were twice as likely to accept a vaccine with 95% effectiveness and 5% adverse effects compared to females (aOR: 2.01; 95% CI 1.05–3.86). We found that 156/377 (41.3%) of respondents were willing to purchase a COVID-19 vaccine and of these participants 71.1% were willing to pay between Indonesian Rupiah (IDR) 50,000–150,000 (US$ 3.33–10.00). In conclusion, the acceptance rate of a hypothetical COVID-19 vaccine varied based on effectiveness and the risk of adverse effects.
Collapse
|
7
|
Viveiros Rosa SG, Santos WC. Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry. Pharm Pat Anal. [DOI: 10.4155/ppa-2021-0023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.
Collapse
|
8
|
Abou Ghayda R, Lee KH, Han YJ, Ryu S, Hong SH, Yoon S, Jeong GH, Yang JW, Lee HJ, Lee J, Lee JY, Effenberger M, Eisenhut M, Kronbichler A, Solmi M, Li H, Jacob L, Koyanagi A, Radua J, Park MB, Aghayeva S, Ahmed MLCB, Al Serouri A, Al-Shamsi HO, Amir-Behghadami M, Baatarkhuu O, Bashour H, Bondarenko A, Camacho-Ortiz A, Castro F, Cox H, Davtyan H, Douglas K, Dragioti E, Ebrahim S, Ferioli M, Harapan H, Mallah SI, Ikram A, Inoue S, Jankovic S, Jayarajah U, Jesenak M, Kakodkar P, Kebede Y, Kifle M, Koh D, Males VK, Kotfis K, Lakoh S, Ling L, Llibre-Guerra J, Machida M, Makurumidze R, Mamun MA, Masic I, Van Minh H, Moiseev S, Nadasdy T, Nahshon C, Ñamendys-Silva SA, Yongsi BN, Nielsen HB, Nodjikouambaye ZA, Ohnmar O, Oksanen A, Owopetu O, Parperis K, Perez GE, Pongpirul K, Rademaker M, Rosa S, Sah R, Sallam D, Schober P, Singhal T, Tafaj S, Torres I, Torres-Roman JS, Tsartsalis D, Tsolmon J, Tuychiev L, Vukcevic B, Wanghi G, Wollina U, Xu RH, Yang L, Zaidi Z, Smith L, Shin JI. The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta-analysis. J Med Virol 2022; 94:2402-2413. [PMID: 35099819 PMCID: PMC9015248 DOI: 10.1002/jmv.27610] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 12/20/2021] [Accepted: 01/18/2022] [Indexed: 02/05/2023]
Abstract
The aim of this study is to provide a more accurate representation of COVID‐19's case fatality rate (CFR) by performing meta‐analyses by continents and income, and by comparing the result with pooled estimates. We used multiple worldwide data sources on COVID‐19 for every country reporting COVID‐19 cases. On the basis of data, we performed random and fixed meta‐analyses for CFR of COVID‐19 by continents and income according to each individual calendar date. CFR was estimated based on the different geographical regions and levels of income using three models: pooled estimates, fixed‐ and random‐model. In Asia, all three types of CFR initially remained approximately between 2.0% and 3.0%. In the case of pooled estimates and the fixed model results, CFR increased to 4.0%, by then gradually decreasing, while in the case of random‐model, CFR remained under 2.0%. Similarly, in Europe, initially, the two types of CFR peaked at 9.0% and 10.0%, respectively. The random‐model results showed an increase near 5.0%. In high‐income countries, pooled estimates and fixed‐model showed gradually increasing trends with a final pooled estimates and random‐model reached about 8.0% and 4.0%, respectively. In middle‐income, the pooled estimates and fixed‐model have gradually increased reaching up to 4.5%. in low‐income countries, CFRs remained similar between 1.5% and 3.0%. Our study emphasizes that COVID‐19 CFR is not a fixed or static value. Rather, it is a dynamic estimate that changes with time, population, socioeconomic factors, and the mitigatory efforts of individual countries. Europe showed the highest COVID‐19 case fatality rate (CFR) until mid‐October 2020, and North America and South America follows. Asia showed the highest CFR since the first confirmed case of COVID‐19 emerged, however, it had shown a declining tendency since March 2020. CFRs in high‐income countries showed an explosive increase compared with those in low‐income countries, which can be interpreted as due to the under‐reporting of mortality cases from COVID‐19.
Collapse
Affiliation(s)
- Ramy Abou Ghayda
- Urology Institute, University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA
| | - Keum Hwa Lee
- Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Young Joo Han
- Hospital Medicine Center, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
| | - Seohyun Ryu
- Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Sung Hwi Hong
- Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Sojung Yoon
- Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Gwang Hum Jeong
- College of Medicine, Gyeongsang National University, Jinju, Republic of Korea
| | - Jae Won Yang
- Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
| | - Hyo Jeong Lee
- Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Jinhee Lee
- Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
| | - Jun Young Lee
- Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
| | - Maria Effenberger
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria
| | - Michael Eisenhut
- Luton & Dunstable University Hospital NHS Foundation Trust, Luton, UK
| | - Andreas Kronbichler
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria
| | - Marco Solmi
- Department of Psychiatry, University of Ottawa, Ontario, Canada.,Department of Mental Health, The Ottawa Hospital, Ontario, Canada.,Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa, Ottawa, Ontario, Canada.,School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Han Li
- University of Florida College of Medicine, Gainesville, Florida, USA
| | - Louis Jacob
- Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France.,Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain
| | - Ai Koyanagi
- Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.,ICREA, Barcelona, Spain
| | - Joaquim Radua
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.,Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden
| | - Myung Bae Park
- Department of Gerontology Health and Welfare, Pai Chai University, Daejeon, Republic of Korea
| | - Sevda Aghayeva
- Department of Gastroenterology, Azerbaijan Medical University School of Medicine, Baku, Azerbaijan
| | - Mohamed L C B Ahmed
- Research Unit in Epidemiology and Diversity of Microorganisms, Department of Biology, University of Nouakchott Al Aasriya, Nouakchott, Mauritania
| | | | - Humaid O Al-Shamsi
- College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.,Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates
| | - Mehrdad Amir-Behghadami
- Iranian Center of Excellence in Health Management (IceHM), School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran.,Student Research Committee (SRC), Tabriz University of Medical Sciences, Tabriz, Iran.,Road Traffic Injury Research Center, Iranian International Safe Community Support Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Oidov Baatarkhuu
- School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
| | - Hyam Bashour
- Department of Family and Community Medicine, Faculty of Medicine, Damascus University, Damascus, Syria
| | | | - Adrian Camacho-Ortiz
- Servicio de Infectología, Hospital Universitario "Dr José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | - Franz Castro
- Department of Research and Health Technology Assessment, Gorgas Memorial Institute for Health Studies, Panama City, Panama
| | - Horace Cox
- Ministry of Health Guyana, Georgetown, Guyana
| | - Hayk Davtyan
- Tuberculosis Research and Prevention Center NGO, Yerevan, Armenia
| | - Kirk Douglas
- Centre for Biosecurity Studies, University of the West Indies, Cave Hill, St. Michael, Barbados
| | - Elena Dragioti
- Department of Health, Medicine and Caring Sciences, Pain and Rehabilitation Centre, Linkoping University, Linkoping, Sweden
| | - Shahul Ebrahim
- Faculty of Medicine, University of Sciences, Techniques, and Technology, Bamako, Mali
| | - Martina Ferioli
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Respiratory and Critical Care Unit, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Harapan Harapan
- Medical Research Unit, School of Medicine Universitas Syiah Kuala, Banda Aceh, Indonesia
| | - Saad I Mallah
- School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen, Kingdom of Bahrain
| | - Aamer Ikram
- National Institute of Health, Islamabad, Pakistan
| | - Shigeru Inoue
- Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan
| | - Slobodan Jankovic
- Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
| | - Umesh Jayarajah
- Postgraduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka
| | - Milos Jesenak
- Department of Pediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
| | - Pramath Kakodkar
- School of Medicine, National University of Galway Ireland, Galway, Ireland
| | - Yohannes Kebede
- Department of Health, Behavior, and Society, Faculty of Public Health, Jimma University, Jimma, Ethiopia
| | - Meron Kifle
- Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - David Koh
- Saw Swee Hock School of Public Health, National University of Singapore, Siangapore
| | - Visnja K Males
- Division of Endocrinology, Diabetes and Metabolic Disease in Split, Clinical Hospital Centre Split, School of Medicine Split, Šoltanska 1, Split, Croatia
| | - Katarzyna Kotfis
- Department Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, Szczecin, Poland
| | - Sulaiman Lakoh
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Lowell Ling
- Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
| | - Jorge Llibre-Guerra
- Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
| | - Masaki Machida
- Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan
| | - Richard Makurumidze
- Department of Community Medicine, Department of Primary Care Sciences, University of Zimbabwe, Faculty of Medicine and Health Sciences, Harare, Zimbabwe
| | - Mohammed A Mamun
- Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka, Bangladesh.,Department of Public Health, Daffodil International University, Dhaka, Bangladesh.,CHINTA Research Bangladesh, Dhaka, Bangladesh
| | - Izet Masic
- Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina
| | - Hoang Van Minh
- Center for Population Health Sciences, Hanoi University of Public Health, Hanoi, Vietnam
| | - Sergey Moiseev
- Sechenov First Moscow State Medical University, Moscow, Russia
| | - Thomas Nadasdy
- Department of Dermatology, "St. Parascheva" Clinical Hospital of Infectious Diseases, Galati, Romania
| | - Chen Nahshon
- Department of Gynecologic Surgery and Oncology, Carmel Medical Center, Haifa, Israel
| | - Silvio A Ñamendys-Silva
- Instituto Nacional de Cancerología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | - Blaise N Yongsi
- Institute for Training & Research in Population Studies (IFORD), The University of Yaoundé II, Soa, Cameroon
| | - Henning B Nielsen
- Department of Anaesthesia and Intensive Care, Zealand University Hospital Roskilde, Roskilde, Denmark
| | - Zita A Nodjikouambaye
- Mobile Laboratory for Hemorrhagic and Respiratory Viruses in Ndjamena, Ndjamena, Chad
| | - Ohnmar Ohnmar
- Department of Medical Research (Lower Myanmar), Myanmar Health Ministry, Yangon, Myanmar
| | | | - Oluwatomi Owopetu
- Department of Community Medicine, University College Hospital, Ibadan, Nigeria
| | - Konstantinos Parperis
- Department of Internal Medicine, University of Cyprus Medical School, Nicosia, Cyprus
| | - Gonzalo E Perez
- Division of Cardiology, Clínica Olivos, Buenos Aires, Argentina
| | - Krit Pongpirul
- Department of Preventive Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Marius Rademaker
- Waikato Clinical School, Auckland University Medical School, Hamilton, New Zealand
| | - Sandro Rosa
- College of Pharmacy, Federal Fluminense University, Niterói, Rio de Janeiro, Brazil.,Pharmacy Division, National Institute of Industrial Property, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Ranjit Sah
- National Public Health Laboratory, Kathmandu, Nepal
| | - Dina Sallam
- Department of Pediatrics & pediatric nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | - Patrick Schober
- Department of Anesthesiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Tanu Singhal
- Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India
| | - Silva Tafaj
- University Hospital Shefqet Ndroqi, Tirana, Albania
| | | | | | | | - Jadamba Tsolmon
- Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
| | | | - Batric Vukcevic
- Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
| | - Guy Wanghi
- Unit of Physiology, Department of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Uwe Wollina
- Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
| | - Ren-He Xu
- Centre of Reproduction, Development and Aging, Faculty of Health Sciences, Institute of Translational Medicine, University of Macau, Taipa, Macau, China
| | - Lin Yang
- Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Canada.,Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, Canada
| | - Zoubida Zaidi
- Faculty of Medicine, University Ferhat Abbas, Setif, Algeria
| | - Lee Smith
- The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
| | - Jae Il Shin
- Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
9
|
Fajar JK, Ilmawan M, Mamada SS, Mutiawati E, Husnah M, Yusuf H, Nainu F, Sirinam S, Keam S, Ophinni Y, Rosiello F, Fahriani M, Rosa SGV. Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis. Narra J 2021; 1:e48. [PMID: 38450213 PMCID: PMC10914045 DOI: 10.52225/narra.v1i3.48] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Accepted: 11/26/2021] [Indexed: 02/05/2023]
Abstract
This study was conducted to determine the prevalence of prolonged neuromuscular symptoms, including fatigue, anosmia, headache, myalgia, and joint pain in COVID-19 survivors hospitalized with mild, moderate, or severe infections worldwide. The search was conducted up to January 30th, 2021 using three databases (PubMed, Scopus, and Web of Science) to identify potentially eligible studies. Data on study characteristics, follow-up characteristics, and severity of COVID-19 during hospitalization were collected in accordance with PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of relevant articles. The estimated prevalence of specific prolonged neuromuscular symptoms and the association between COVID-19 severity and occurrence of prolonged neuromuscular symptoms was analyzed wherever appropriate. Database search yielded 4,050 articles and 22 articles were included for meta-analysis. The estimated prevalence of prolonged fatigue was recorded in 21.2% (95%CI: 11.9%- 34.8%) of 3,730 COVID-19 survivors. Persistent anosmia was recorded in 239 of 2,600 COVID-19 survivors (9.7%, 95%CI: 6.1%-15.2%). In 84 out of 2,412 COVID-19 survivors (8.9%, 95%CI: 3.2%-22.6%), prolonged headache was observed. A total of 53 out of 1,125 COVID-19 patients (5.6%, 95%CI: 2.1%-14.2%) complained of persistent myalgia even after being discharged from the hospital. The prevalence of prolonged joint pain was in 15.4% (95%CI: 8.2%-27.2%) of subjects. Due to data scarcity on COVID-19 severity and prolonged neuromuscular symptoms, association analysis could not be conducted. Widespread concern regarding long-term impacts of COVID-19 was raised after several studies reported prolonged symptoms in COVID-19 survivors. Numerous theories have been proposed to address this concern; however, as the research on this pandemic is still ongoing, no explanation is definitive yet. Therefore, follow-up studies in COVID-19 survivors after recovery from COVID-19 are warranted to determine the pathogenesis of prolonged symptoms. PROSPERO registration: CRD42021242332.
Collapse
Affiliation(s)
- Jonny K Fajar
- Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
| | | | - Sukamto S Mamada
- Faculty of Pharmacy, Hasanuddin University, Tamalanrea, Makassar, Indonesia
| | - Endang Mutiawati
- Department of Neurology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
- Department of Neurology, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia
| | - Milda Husnah
- Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, Indonesia
| | - Hanifah Yusuf
- Department of Pharmacology, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
| | - Firzan Nainu
- Faculty of Pharmacy, Hasanuddin University, Tamalanrea, Makassar, Indonesia
| | - Salin Sirinam
- Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
| | - Synat Keam
- School of Medicine, University of Western Australia, Perth, Western Australia, Australia
| | - Youdiil Ophinni
- Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Harvard University, Cambridge, MA, USA
- Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Francesco Rosiello
- Department of Public Health and Infectious Disease, Sapienza-University of Rome, Rome, Italy
| | - Marhami Fahriani
- Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
| | - Sandro G V Rosa
- Diretoria de Patentes, Divisão De Farmácia - Instituto Nacional Da Propriedade Industrial, Rio de Janeiro, Brasil
- Programa De Pós-Graduação Em Ciências Aplicadas a Produtos Para Saúde, Faculdade De Farmácia, Universidade Federal Fluminense, Brasil
| |
Collapse
|
10
|
Hassan W, Kazmi SK, Tahir MJ, Ullah I, Royan HA, Fahriani M, Nainu F, Rosa SGV. Global acceptance and hesitancy of COVID-19 vaccination: A narrative review. Narra J 2021; 1:e57. [PMID: 38450215 PMCID: PMC10914054 DOI: 10.52225/narra.v1i3.57] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 11/29/2021] [Indexed: 02/05/2023]
Abstract
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health threat to human civilization and has disrupted many aspects of the community around the globe. Vaccination is one of the prominent measures to control the COVID-19 pandemic. More than 120 vaccines have entered human clinical trials and at least 8 vaccines have been fully approved. However, the success of the COVID-19 vaccination programs depends on how the community accepts the vaccines. Despite COVID-19 vaccination having been initiated for a while now, more than 50% of the global population have not been vaccinated. In some low- and middle-income countries (LMICs), the vaccine coverage is less than 20%. Since the decision to accept the new vaccine is complex, understanding the factors underpinning vaccine acceptance is critical. This review aimed to summarize the COVID-19 vaccine acceptance rate around the globe as well as its associated determinants. Information from this study might be important to formulate effective strategies to increase the COVID-19 vaccine coverage, and to be able to achieve herd immunity.
Collapse
Affiliation(s)
- Wardah Hassan
- Dow University of Health Sciences, Karachi, Pakistan
| | - Syeda K Kazmi
- Dow University of Health Sciences, Karachi, Pakistan
| | - Muhammad J Tahir
- Lahore General Hospital, Lahore, Pakistan
- Ameer-ud-Din Medical College, Affiliated with University of Health and Sciences, Lahore, Pakistan
| | - Irfan Ullah
- Kabir Medical College, Gandhara University, Peshawar, Pakistan
- Naseer Teaching Hospital, Peshawar, Pakistan
| | - Hibban A Royan
- Center for Indonesian Medical Students' Activities (CIMSA), Banda Aceh, Indonesia
| | - Marhami Fahriani
- Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia
| | - Firzan Nainu
- Faculty of Pharmacy, Hasanuddin University, Makassar, Sulawesi Selatan, Indonesia
| | - Sandro G V Rosa
- Diretoria de Patentes, Divisão de Farmácia - Instituto Nacional da Propriedade Industrial, Rio de Janeiro, Brasil
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos para Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Brasil
| |
Collapse
|
11
|
Viveiros Rosa SG, Santos WC. Vaccines and treatments for Zika virus infection: patent status, triumphs and challenges. Pharm Pat Anal 2021; 10:209-13. [PMID: 34488495 DOI: 10.4155/ppa-2021-0014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
12
|
Abstract
INTRODUCTION Zika virus (ZIKV) is transmitted to humans throughout bites of Aedes mosquitoes. ZIKV infection may be asymptomatic in most cases, but it may cause fever, headache, muscle pain, and rash. Guillain-Barré syndrome also may be associated with the infection. Furthermore, the Pan American Health Organization informed 3,715 cases of the congenital ZIKV syndrome (CZS) in the Americas from 2015 - 2017, which may include microcephaly and other craniofacial deformities. AREAS COVERED This review identifies patent documents on repositioning for ZIKV infection treatment of already approved drugs or phases II/III investigated drugs for other diseases. Thirty-six patents were found reporting compounds with anti-ZIKV activity with application dates ranging from 2015 to 2019. EXPERT OPINION The main drugs claimed in patents were ribavirin, sofosbuvir, and alpha interferons. Preventing CZS is one of the most significant challenges in ZIKV infection. Therefore, repositioning sofosbuvir and niclosamide, that pose no danger for pregnant women, is a particular issue to be considered for clinical tests involving ZIKV disease. Given the substantial costs and developing time of new a drug, repositioning of old drugs is becoming an attractive alternative for diseases with neglected treatments.
Collapse
Affiliation(s)
- Sandro G Viveiros Rosa
- Diretoria de Patentes, Divisão De Farmácia - Instituto Nacional Da Propriedade Industrial , Rio de Janeiro, Brasil.,Programa De Pós-Graduação Em Ciências Aplicadas a Produtos Para Saúde, Faculdade De Farmácia, Universidade Federal Fluminense , Brasil
| | - Iolanda M Fierro
- cAcademia De Propriedade Intelectual - Instituto Nacional Da Propriedade Industrial , Rio de Janeiro, Niteroi City, Rio de Janeiro, Brazil
| | - Wilson C Santos
- Programa De Pós-Graduação Em Ciências Aplicadas a Produtos Para Saúde, Faculdade De Farmácia, Universidade Federal Fluminense , Brasil.,Instituto Teófilo Hernando, Departamento De Farmacología, Facultad De Medicina, Universidad Autónoma De Madrid , Madrid, Spain
| |
Collapse
|
13
|
Abstract
The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
Collapse
Affiliation(s)
- Sandro G. Viveiros Rosa
- Universidade Federal FluminenseUniversidade Federal FluminenseBrazilUniversidade Federal Fluminense, Rio de Janeiro, Brazil.
| | - Wilson C. Santos
- Universidade Federal FluminenseUniversidade Federal FluminenseBrazilUniversidade Federal Fluminense, Rio de Janeiro, Brazil.
| |
Collapse
|
14
|
Viveiros-Rosa SG, Regis EG, Santos WC. Vector competence of Culex mosquitoes (Diptera: Culicidae) in Zika virus transmission: an integrative review. Rev Panam Salud Publica 2020; 44:e7. [PMID: 32025230 PMCID: PMC6996147 DOI: 10.26633/rpsp.2020.7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Accepted: 11/07/2019] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE To identify studies on the competence of Culex mosquitoes as vectors for the transmission of Zika virus (ZIKV) around the globe. METHODS We performed an integrative review to identify relevant articles on specific experiments to determine whether Culex mosquitoes are vectors for ZIKV. The sources we used for our research were the Brazilian Periódicos CAPES electronic portal (MEDLINE/PubMed, ScienceDirect Journals, Nature Publishing Group, SciELO, Springer Link, and 250 other databases) and gray literature. RESULTS We identified 344 studies, of which 36 were considered for this review. In 8 studies, infection in salivary glands of Culex quinquefasciatus, Culex restuans, Culex tarsalis, and Culex coronator was detected. Cx. quinquefasciatus was the most studied among those confirmed as potential ZIKV vectors, and only strains of Asian lineages (THA/2014/SV0127-14; SZ01 (2016)) and American lineages (BRPE243 (2015); PRVABC59 (2015)) can infect the salivary glands of Culex mosquitoes. The tested African strains (MR766 and DAK AR 41525) were unable to infect salivary glands. CONCLUSIONS There is still a lack of compelling evidence that indicates Culex spp. are a competent ZIKV vector, but they should remain a target for further monitoring studies, especially regarding ZIKV transmission to other species. Furthermore, studies should not be limited to studying whether their salivary glands are infected.
Collapse
Affiliation(s)
- Sandro G. Viveiros-Rosa
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde, Faculdade de FarmáciaUniversidade Federal FluminenseNiteróiRio de JaneiroBrasilPrograma de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brasil.
| | - Eduardo G. Regis
- Instituto Nacional da Propriedade IndustrialDivisão de BiofármacosRio de JaneiroBrasilInstituto Nacional da Propriedade Industrial, Divisão de Biofármacos, Rio de Janeiro, Rio de Janeiro, Brasil.
| | - Wilson C. Santos
- Programa de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde, Faculdade de FarmáciaUniversidade Federal FluminenseNiteróiRio de JaneiroBrasilPrograma de Pós-Graduação em Ciências Aplicadas a Produtos Para Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brasil.
| |
Collapse
|